Clinical Trial Update: An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory study evaluating BZE2204 CAR-T cells targeting CD19/CD22/BCMA for relapsed or refractory autoimmune diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Immune Thrombocytopenia
• Systemic Lupus Erythematosus

Drugs mentioned

• BZE2204 CAR-T cells (CD19/CD22/BCMA CAR-T cells)

Snippet

Sponsor: Shanghai Cell Therapy Group Co.,Ltd | Conditions: Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP) | EARLY_Phase 1 | Status: RECRUITING